Global Hepatitis Drugs Market – Drivers, Opportunities, Trends, and Forecasts: 2017–2023

  • Product Code:
  • Published Date:
    17 Jul 2021
  • Region:
  • Pages:
  • Category:
    Healthcare & Pharmaceuticals
  • Publisher:

Impact Analysis on the Growth of Market

Activating Probable Propositions Amidst COVID-19 Crisis

With things going haywire, we analyze key points to make sure that the businesses around the globe are completely prepared to tackle potential implications caused by COVID-19. Be it protecting employees, customers or the overall business operations, we ensure that the employers take the right decisions, make strategic investments and maintain a healthy work culture along with taking probable measures to minimize the financial loss. Know More


Market Overview:

Overview: Hepatitis is a medical condition where the liver is predominantly affected, which can also affect the digestive system and brain. There are three major types of hepatitis condition – HAV, HBV, and HCV. HCV is a major public health problem that attacks the liver and leads to inflammation. Certain drugs, toxins, heavy alcohol use, bacterial and viral infections can cause hepatitis infection. Hepatitis C infection can bring both acute and chronic hepatitis disease. Approximately, 80% of the patients get chronically infected with Hepatitis C disease. Hepatitis C Virus (HCV) spreads through the blood of an infected individual by the use of shared needles or supplies used to infuse drugs. Vaccines are available only for Hepatitis A and Hepatitis B viruses. Research into the development of a vaccine for Hepatitis C is under way.
Factors such as rise in injection drug users, increase in awareness, presence of unmet need, and anticipated launch of new drugs are expected to drive the market growth during the forecast period. The market is witnessing the emerging trend of pediatric combination vaccines, which protect against multiple causative agents and thereby reduce the costs gain in packaging and administering individual vaccines. The markets in India, Brazil, China, and Russia are also expected to grow at a rapid pace during the forecast period as the prevalence of hepatitis in these countries is high.
The major drivers of the hepatitis drugs market include the second generation DAAs of Olysio and Sovaldi. Second generation DAAs are more efficacious and have lesser adverse effects. Currently, the market players are developing IFN therapies for the treatment of Hepatitis C. These therapies are intended to be all-oral regimens. The HCV drugs segment comprised more than 84% of the total market share in 2016. A major focus in this segment is expected to drive the growth of the hepatitis drugs market in the future.
Market Analysis: The “Global Hepatitis Drugs Market” is estimated to witness a CAGR of 15.0% during the forecast period 2017–2023. The Hepatitis Drugs market is analyzed based on two segments – conditions and regions.
Regional Analysis: The regions covered in the report are the Americas, Europe, Asia Pacific, and Rest of the World (RoW). The Americas is set to be the leading region for the hepatitis drugs market growth followed by Europe. The Asia Pacific and RoW are set to be the emerging regions. Japan is set to be the most attractive destination and in Africa, the popularity and the usage of various HBV and HCV drugs are expected to increase in the coming years.
Therapeutic Application Analysis: The most common hepatitis being viral hepatitis can be caused by either of the five hepatotropic viruses, namely Hepatitis A, Hepatitis B, Hepatitis C, Hepatitis D, and Hepatitis E. The non-viral hepatitis can be caused by autoimmune diseases, alcohol, few of prescription medications, and toxic substances. Globally, the industry players are focusing significantly on R&D to gain approval for various clinical trials for future HBV and HCV drugs to be commercially available in the market. The advent of interferon-free combination regimens and DAAs is one of the major drivers for the global hepatitis drugs market, specifically for the HCV market. Moreover, various IFN-regimens are under development as all-oral regimens. These therapies are expected to attain higher SVR and cause lesser side effects than currently approved therapies. The market is also witnessing various mergers, acquisitions, and collaborations among the top players, which is defining the future of the Global Hepatitis Drugs market.
Key Players: Gilead Sciences Inc., Abbvie Inc., Johnson & Johnson, Merck & Co. Inc., GlaxoSmithKline plc, Vertex Pharmaceuticals Inc., Novartis AG, Hoffmann-La Roche Ltd., and other predominate & niche players.
Competitive Analysis: At present, the HCV drugs are dominating the Global Hepatitis Drugs market – but, a lot of new players are focusing on developing HBV drug molecules to gain future business opportunities. Especially, big players along with the collaboration with other SMBs for clinical trials of hepatitis molecules and compounds are coming with new commercial targeted drugs in the market and they are expecting a double-digit growth in the upcoming years. Significant investments in R&D in this market are expected to increase and collaborations, merger & acquisition activities are expected to continue.
Benefits: The report provides complete details about the usage and adoption rate of hepatitis drugs in various therapeutic verticals and regions. With that, key stakeholders can know about the major trends, drivers, investments, vertical player’s initiatives, and government initiatives towards the hepatitis drugs adoption in the upcoming years along with the details of commercial drugs available in the market. Moreover, the report provides details about the major challenges that are going to impact on the market growth. Additionally, the report gives the complete details about the key business opportunities to key stakeholders to expand their business and capture the revenue in the specific verticals to analyze before investing or expanding the business in this market.

Geography Analysis:

The report further discusses the market opportunity, compound annual growth rate (CAGR) growth rate, competition, new technology innovations, market players analysis, government guidelines, export and import (EXIM) analysis, historical revenues, future forecasts etc. in the following regions and/or countries:

  • North America (U.S. & Canada) Market size, Y-O-Y growth, Market Players Analysis & Opportunity Outlook
  • Latin America (Brazil, Mexico, Argentina, Rest of Latin America) Market size, Y-O-Y growth & Market Players Analysis & Opportunity Outlook
  • Europe (U.K., Germany, France, Italy, Spain, Hungary, Belgium, Netherlands & Luxembourg, NORDIC(Finland, Sweden, Norway, Denmark), Ireland, Switzerland, Austria, Poland, Turkey, Russia, Rest of Europe), Poland, Turkey, Russia, Rest of Europe) Market size, Y-O-Y growth Market Players Analys  & Opportunity Outlook
  • Asia-Pacific (China, India, Japan, South Korea, Singapore, Indonesia, Malaysia, Australia, New Zealand, Rest of Asia-Pacific) Market size, Y-O-Y growth & Market Players Analysis & Opportunity Outlook
  • Middle East and Africa  (Israel, GCC (Saudi Arabia, UAE, Bahrain, Kuwait, Qatar, Oman), North Africa, South Africa, Rest of Middle East and Africa) Market size, Y-O-Y growth Market Players Analysis & Opportunity Outlook


1 Industry Outlook 9
1.1 Industry Overview 9
1.2 Industry Trends 10
1.3 Pest Analysis 11
2 Report Outline 12
2.1 Report Scope 12
2.2 Report Summary 12
2.3 Research Methodology 13
2.4 Report Assumptions 13
3 Market Snapshot 14
3.1 Total Addressable Market (TAM) 14
3.2 Disease Overview 15
3.2.1 Hepatitis A 15 Epidemiology 15 Therapy 15
3.2.2 Hepatitis B 15 Epidemiology 15 Therapy 16
3.2.3 Hepatitis C 16 Epidemiology 16 Therapy 17
3.2.4 Hepatitis D 18
3.2.5 Hepatitis E 19
3.3 Disease Transmission 19
3.4 Related Markets 20
4 Market Outlook 21
4.1 Overview 21
4.2 Regulatory Bodies & Standards 21
4.3 Porter 5 (Five) Forces 22
5 Market Characteristics 23
5.1 Evolution 23
5.2 ROADMAP 24
5.3 Market Dynamics 25
5.3.1 Drivers 25 Increasing Demand of Hepatitis Drugs 25 Focus on Advanced DAAs 25 Introduction of IFN-free Therapies 26 Growth of Injection Drug Users 26
5.3.2 Restraints 27 Long Approval Process and Stringent Regulations 27 Side Effects of Hepatitis Drugs 27 Increase in the Number of Generic Drugs 27 Increasing Market Competition 27
5.3.3 Opportunities 28 Significant Increase in Mergers and Acquisitions 28 Emergence of Combination Drugs 28 Preventive Healthcare 28 Focus of Companies on Emerging Market 29
5.3.4 DRO – Impact Analysis 29
6 Trends, Roadmap and Projects 30
6.1 Market Trends & Impact 30
6.2 Technology Roadmap 31
7 Types: Market Size & Analysis 32
7.1 Overview 32
7.2 Hepatitis A Segment 33
7.3 Hepatitis B Segment 34
7.4 Hepatitis C Segment 34
8 Trending Hepatitis Drugs 36
8.1 Overview 36
8.1.1 VEMLIDY 37
8.1.2 EPCLUSA 37
8.1.3 SOVALDI 37
8.1.4 INCIVEK 38
8.1.5 OLYSIO 38
8.1.6 VICTRELIS 38
8.1.7 VIREAD 38
8.1.8 HEPSERA 38
8.1.9 BARACLUDE 39
8.1.10 TYZEKA 39
8.1.11 INTRON A 39
8.1.12 PEGASYS 39
8.1.13 PEGINTRON 40
8.1.14 ROFERON-A 40
8.1.16 REBETOL 40
9 Regions: Market Size & Analysis 41
9.1 OVERVIEW 41 Global Hepatitis Drugs Market by Geographical Segmentation 42
10 Vendor Scenario 43
10.1 Market Share Ranking 2016 44
10.1.1 GILEAD SCIENCES INC. 44 Sovaldi (sofosbuvir) 44 Harvoni (ledipasvir and sofosbuvir) 44 Viread (tenofovir disoproxil fumarate) 45 Hepsera (adefovir dipivoxil) 45
10.1.2 ABBVIE INC. 45 Viekira Pak (ombitasvir, paritaprevir, ritonavir and dasabuvir) 45
10.1.3 JOHNSON & JOHNSON 46 Olysio (simeprevir) 46 Incivo(telaprevir) 46
10.1.4 MERCK & CO. INC. 46 Zepatier (elbasvir and grazoprevir) 46 Victrelis (boceprevir) 47 Peg-Intron (peginterferon alfa-2b) 47 Rebetol (ribavirin) 47 Intron A (interferon alfa-2b, recombinant) 47
10.1.5 GLAXOSMITHKLINE PLC 48 Pediarix Vaccine 48 Twinrix 48 Havrix 48 Epivir (lamivudine) 48
10.1.6 VERTEX PHARMACEUTICALS INC. 48 Incivek (telaprevir) 48
10.1.7 NOVARTIS AG 49 Tyzeka (telbivudine) 49
10.1.8 HOFFMANN-LA ROCHE LTD. 49 Pegasys (peginterferon alfa-2a) 49
11 Vendor Profiles 50
11.1.1 Merck & Co. Inc. 50 Overview 50 Business unit 51 Geographic revenue 52 Recent developments 53 SWOT analysis 54 Business strategies 55
11.1.2 Hoffmann-La Roche Ltd. 56 Overview 56 Business Unit 57 Geographic revenue 58 Recent developments 58 SWOT analysis 60 Business strategies 60
11.1.3 Gilead Sciences 62 Overview 62 Business Unit 63 Geographic revenue 65 Recent developments 65 SWOT analysis 66 Business strategies 66
11.1.4 Novartis AG 67 Overview 67 Business Unit 67 Geographic revenue 69 Recent developments 69 SWOT analysis 71 Business strategies 71
11.1.5 GlaxoSmithKline plc 72 Overview 72 Business Unit 73 Geographic revenue 75 Recent developments 75 SWOT analysis 76 Business strategies 77
12 Global Generalist 78
12.1 Vertex Pharmaceuticals Inc. 78
12.1.1 Overview 78 Recent developments 79
12.1.2 Vertex Pharmaceuticals Inc. in 2015 80
12.2 Johnson & Johnson 81
12.2.1 Overview 81 Recent developments 82
12.2.2 Johnson & Johnson in 2015 83
13 Market Landscape 85
13.1 Market Landscape 85
13.1.1 Mergers & Acquisitions (M&A) 85
Annexure 87
 Acronyms 87
Please enter your personal details below
I want to buy this report
I am willing to know the scope of research
I have customized query over this report
Gilead Sciences Inc,Abbvie Inc,Johnson & Johnson,Merck & Co Inc,Gloxosmithkline PLC
Vertex Pharmaceuticals Inc,Novartis AG,Hoffmann-LA Roche Ltd,Merck & Co Inc,Hoffmann-La Roche Ltd
Gilead Sciences,Novartis AG,GlaxoSmithKline Plc.
Please enter your personal details below
I want to buy this report
I am willing to know the scope of research
I have customized query over this report

Related Reports